Study S000045

A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential Influence on Intragastric pH

ClinicalTrials.gov record

Registration

Registration: NCT01518166
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 70
Start: 2006-05
Primary completion: 2007-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide; DRUG:placebo; DRUG:atorvastatin; DRUG:lisinopril; DRUG:griseofulvin; DRUG:digoxin
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2006-000175-15

Registered primary outcomes

Area under the curve of atorvastatin []
Area under the curve of lisinopril []
Area under the curve of griseofulvin []
Area under the curve of digoxin []

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022294	Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Malm-Erjefält M, Molecular pharmaceutics	2015	Other	PMID 26426736 DOI	registry reference RESULT:26426736